Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: Rapid resolution during treatment with adefovir

Gut

Volumn 49, Issue 6, 2001, Pages 860-863

  Mutimer, D ^a,c   Feraz Neto, B H ^d   Harrison, R ^a   O'Donnell, K ^a   Shaw, J ^a   Cane, P ^b,c   Pillay, D ^b,c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^d HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

Author keywords

Adefovir; Hepatitis B virus; Lamivudine; Liver graft

Indexed keywords

ADEFOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE;

ADULT; ARTICLE; CASE REPORT; GENE SEQUENCE; GRAFT FAILURE; HEPATITIS; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; REINFECTION;

ACUTE DISEASE; ADENINE; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GRAFT REJECTION; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOHISTOCHEMISTRY; LAMIVUDINE; LIVER; LIVER TRANSPLANTATION; MALE; PHOSPHONIC ACIDS;

EID: 0035178709     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.49.6.860     Document Type: Article

References (22)

1. Liver transplantation in European patients with the hepatitis B surface antigen
2. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
3. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
4. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
5. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
6. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
7. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
8. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
9. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
10. A one-year trial of lamivudine for chronic hepatitis B
11. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
12. Recurrent hepatitis B in liver allografts: A distinctive form of rapidly developing cirrhosis
13. Treatment of fibrosing cholestatic hepatitis with lamivudine
14. Successful use of lamivudine for severe acute hepatitis B virus infection in a cardiac transplant recipient
15. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
16. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
17. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
18. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
19. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
20. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
21. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
22. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants